Table 2 Antibacterial activity of piscidin-1 and its designed novel analogs.

From: Piscidin-1-analogs with double L- and D-lysine residues exhibited different conformations in lipopolysaccharide but comparable anti-endotoxin activities

Peptide

Minimum inhibitory conc. (MIC) in μM against bacteria

1

2

3

4

5

6

7

8

9

10

11

Piscidin-1

1.25 ± 0.3

2.5 ± 0.4

5.0 ± 0.7

2.5 ± 0.4

2.5 ± 0.4

2.5 ± 0.4

2.5 ± 0.4

6.0 ± 0.7

8.0 ± 1.0

3.8 ± 0.5

3.0 ± 0.3

T15,21K Piscidin-1

1.25 ± 0.3

2.5 ± 0.4

2.5 ± 0.4

2.5 ± 0.4

1.25 ± 0.3

2.5 ± 0.4

1.25 ± 0.3

5.0 ± 0.7

5.0 ± 0.7

3.0 ± 0.4

2.0 ± 0.3

T15,21dK Piscidin-1

5.0 ± 0.7

5.0 ± 0.7

10.0 ± 1.4

5.0 ± 0.7

5.0 ± 0.7

10.0 ± 1.4

5.0 ± 0.7

9.0 ± 1.3

9.0 ± 1.3

5.0 ± 0.7

5.0 ± 0.7

T15K Piscidin-1

1.25 ± 0.3

2.5 ± 0.4

2.5 ± 0.4

1.25 ± 0.3

1.25 ± 0.3

2.5 ± 0.4

2.5 ± 0.4

7.0 ± 1.0

8.5 ± 1.2

3.2 ± 0.4

3.5 ± 0.4

T15dK Piscidin-1

2.5 ± 0.4

2.5 ± 0.4

10.0 ± 1.4

2.5 ± 0.4

2.5 ± 0.4

5.0 ± 0.7

2.5 ± 0.4

7.5 ± 1.0

9.0 ± 1.3

3.6 ± 0.5

4.0 ± 0.6

Gentamycin

0.8

1.6

>100

>100

>50

>100

3.2

1.46

0.048

3.26

3.14

Norfloxacin

1.22

2.44

>150

2.44

39.0

>150

>150

2.19

0.39

0.125

0.125

  1. MIC values are given as the means of three independent experiments each performed in duplicate ± the standard deviation.
  2. 1. Staphylococcus aureus (ATCC 25923), 2. Staphylococcus aureus (ATCC 29213), 3. Staphylococcus aureus (ATCC 700699 MRSA), 4. Staphylococcus aureus (ATCC 33592 Gentamycin Resistant), 5. Staphylococcus aureus (ATCC BAA-44 MRSA), 6. Staphylococcus aureus (ATCC 700698 MRSA), 7. Staphylococcus aureus (ATCC 1708 MRSA), 8. P. aeruginosa (ATCC BAA-427), 9. B. subtilis (ATCC 6633), 10. K. pneumoniae (ATCC 27736), 11. E. coli (ATCC 25922).
Back to article page